Articolul precedent |
Articolul urmator |
323 3 |
Ultima descărcare din IBN: 2024-04-01 11:34 |
SM ISO690:2012 TOMACINSCHII, Victor, FINCIUC, Veronica, GRECU, Ana, DUDNIC, Cristina, URESCU, Dumitrița, SUŞCHEVICI, Marina, ROBU, Maria. Impact of targeted treatment in non-Hodgkin's lymphoma with primary lymph node involvement. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 108. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 108-108 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Non-Hodgkin's lymphomas (NHL) are malignant hematopoietic tumors that develop from lymphoid tissue. Primary lymph node involvement (l/n) is the most common localization of it, summing 52-70%. The integration of Rituximab (R) in combination with conventional polychemotherapy (PChT) in the NHL treatment. Objective of the study. To evaluate the therapeutic impact of the use of R in combination with conventional PChT in the treatment of nodal onset NHL. Material and Methods. A descriptive cohort study was performed, which included 80 patients diagnosed with NHL monitored at the PMSI Oncological Institute. Statistical processing of materials was performed using Microsoft Excel and IBM SPSS statistics v.26. Results. In the study participated: men-39, women-41. The mean age of the patients was 56.09±13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal l/n-7.5%, and in abdominals in 7.5%. Stages I-II were determined in 21(26.2%) patients, stages III-IV in 59(73.7%) cases. Aggressive NHLs were diagnosed in 52(65.0%) patients, indolent NHLs in 28(35.0%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied-group 1(G1), and in 19(23.8%) cases conventional PChT was applied-group 2(G2). The overall response rate(ORR) in G1 was 86.8%, in G2-63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients in G2-47.3% of cases. Conclusion. The use of Rituximab increased the ORR rate (86.8% vs. 63.1%), the frequency of CR (63.9% vs. 47.3%) and PFS (20 months vs. 12 months (p <0.05)). |
||||||
Cuvinte-cheie non-Hodgkin's lymphoma, lymph nodes, treatment, limfom non-Hodgkin, ganglioni limfatici, Tratament |
||||||
|